Emergent Biosolutions (EBS)
NYSE:EBS
Want to see EBS full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.09Last Year’s EPS
0.16Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized meaningful operational and financial progress: revenue and adjusted EBITDA exceeded guidance, cash, liquidity and net debt improved materially, refinancing enhanced flexibility, and strategic initiatives (international MCM expansion, product line extensions, manufacturing partnerships) are gaining traction. Notable challenges include comparability to a large 2025 order, constrained U.S. pricing dynamics, an expected $50.4M contingent cash outflow in Q2, and reduced R&D spend. On balance, the positives—strong execution against the turnaround plan, improved balance sheet metrics, and concrete growth catalysts—outweigh the negatives in the near term.Company Guidance
Revenue Above Guidance
Q1 2026 revenue of $156 million, which exceeded the high end of prior guidance ($135M–$155M). Q2 revenue guidance: $170M–$185M.
Adjusted EBITDA and Margins
Adjusted EBITDA of $36 million in Q1 2026 with an adjusted EBITDA margin of 23%. Company updated full-year adjusted EBITDA guidance to $155M–$175M (now includes non-cash stock compensation add-back).
Strong Gross Margin and Cost Discipline
Q1 adjusted gross margin of 52%. Operating expenses decreased by $10 million year-over-year and R&D spend declined by ~33% versus Q1 2025, reflecting tighter cost control.
Improved Cash, Liquidity and Working Capital
Cash balance improved by $11 million year-over-year to $160 million; total liquidity increased to $260 million. Net working capital improved by over $100 million since Q1 2025.
Material Debt Reduction and Refinancing
Net debt reduced by $122 million (approximately 22%) versus Q1 2025; net leverage improved to 2.4x adjusted EBITDA (from 2.7x). April 2026 refinancing lowered interest costs, extended maturities to 2031, decreased term loan debt by $100M versus Q1 2025, and added a $75M delayed draw term loan and a $50M revolver.
Share Repurchase Activity
Repurchased $9 million of shares in Q1 2026 (900,000 shares). Since program start in 2025, approximately $34 million repurchased; $46.5 million of authorized repurchase capacity remains.
MCM International Expansion
International MCM revenue represented 37% of total MCM revenue in Q1 2026 (up from historical mid-teens), demonstrating diversification beyond the U.S. government and higher-margin international sales.
Contract Wins and Orders
Announced a $140 million multiproduct agreement with Canada, a $54 million legal award with ASPR, and approximately $21.5 million delivery order to supply BioThrax to the U.S. (Department referenced). Company received four contracted product orders in the quarter.
Product and Manufacturing Partnerships
Launched NARCAN line extensions (carrying case and multipack) with initial strong performance; >100 million NARCAN doses delivered since 2016. Strategic manufacturing partnerships: U.S. distribution agreement with Substipharm for Japanese encephalitis vaccine and manufacturing partnership with SAB Biotherapeutics to support a type 1 diabetes candidate; plans to expand Canton facility capability.
Maintained Full-Year Revenue Guidance
Maintained full-year total revenue guidance of $720 million to $760 million and adjusted gross margin guidance of 45%–47%.
EBS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EBS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $8.23 | $8.47 | +2.92% |
Feb 26, 2026 | $11.10 | $8.15 | -26.58% |
Oct 29, 2025 | $9.40 | $12.84 | +36.60% |
Aug 06, 2025 | $6.03 | $8.24 | +36.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Emergent Biosolutions (EBS) report earnings?
Emergent Biosolutions (EBS) is schdueled to report earning on Aug 11, 2026, TBA (Confirmed).
What is Emergent Biosolutions (EBS) earnings time?
Emergent Biosolutions (EBS) earnings time is at Aug 11, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EBS EPS forecast?
EBS EPS forecast for the fiscal quarter 2026 (Q2) is -0.09.